Since immunotherapy and CDK4/6 inhibition are currently in clinical trials for prostate cancer with CDK12 mutations, there will be opportunities in future to determine the extent to which CDK12d classification is associated with disease response to various targeted therapies. This evidence concerns the gene CDK12 and Familial prostate cancer.